These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. [The value of VALUE--a hypertension study which compared valsartan with amlodipine. New data support early, optimal blood pressure control for high-risk patients]. Nilsson PM Lakartidningen; 2004 Jul; 101(30-31):2426-7. PubMed ID: 15314941 [No Abstract] [Full Text] [Related]
6. Two amlodipine/ARB combinations for hypertension. Med Lett Drugs Ther; 2007 Dec; 49(1276):101-2. PubMed ID: 18084152 [No Abstract] [Full Text] [Related]
8. Effects of the angiotensin-1 receptor blocker valsartan compared with amlodipine on renal hemodynamics. Epstein M; Hollenberg NK Am J Hypertens; 2004 Jul; 17(7):638-9; author reply 639-40. PubMed ID: 15233985 [No Abstract] [Full Text] [Related]
10. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Julius S; Kjeldsen SE; Weber M; Brunner HR; Ekman S; Hansson L; Hua T; Laragh J; McInnes GT; Mitchell L; Plat F; Schork A; Smith B; Zanchetti A; Lancet; 2004 Jun; 363(9426):2022-31. PubMed ID: 15207952 [TBL] [Abstract][Full Text] [Related]
11. [VALUE study underscores the significance of reaching aimed blood pressure values for minimizing cardiovascular risks]. Praxis (Bern 1994); 2004 Oct; 93(42):1748. PubMed ID: 15529964 [No Abstract] [Full Text] [Related]
12. Single-pill combination of amlodipine and valsartan in the management of hypertension. Flack JM; Hilkert R Expert Opin Pharmacother; 2009 Aug; 10(12):1979-94. PubMed ID: 19606937 [TBL] [Abstract][Full Text] [Related]
13. [Preventing end-organ damage in hypertension. What is the significance of the VALUE Study for general practice?]. Zidek W MMW Fortschr Med; 2004 Jul; 146(27-28):41. PubMed ID: 15526662 [No Abstract] [Full Text] [Related]
14. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Weber MA; Julius S; Kjeldsen SE; Brunner HR; Ekman S; Hansson L; Hua T; Laragh JH; McInnes GT; Mitchell L; Plat F; Schork MA; Smith B; Zanchetti A Lancet; 2004 Jun; 363(9426):2049-51. PubMed ID: 15207957 [TBL] [Abstract][Full Text] [Related]
15. Exforge HCT. Med Lett Drugs Ther; 2009 Jun; 51(1314):47. PubMed ID: 19528888 [No Abstract] [Full Text] [Related]
16. [VALUE study underscores the importance of reaching goal blood pressure values for minimization of cardiovascular risks]. Praxis (Bern 1994); 2004 Oct; 93(44):1836. PubMed ID: 15559910 [No Abstract] [Full Text] [Related]
18. Effects of exercise therapy alone and in combination with a calcium channel blocker or an angiotensin receptor blocker in hypertensive patients. Ohta M; Tajiri Y; Yamato H; Ikeda M Clin Exp Hypertens; 2012; 34(7):523-9. PubMed ID: 22559159 [TBL] [Abstract][Full Text] [Related]
19. [A first drug combination for the treatment of arterial hypertension with a calcium channel antagonist (amlodipine besylate) and an angiotensin receptor blocker (valsartan): Exforge]. Krzesinski JM; Scheen AJ Rev Med Liege; 2007 Nov; 62(11):688-94. PubMed ID: 18217647 [TBL] [Abstract][Full Text] [Related]
20. [Control of systolic blood pressure in the VALUE trial after 12 months]. Schmieder RE; Handrock R; Dtsch Med Wochenschr; 2003 Mar; 128(10):485-6. PubMed ID: 12627338 [No Abstract] [Full Text] [Related] [Next] [New Search]